Third Arc Bio Raises $52 Million Series A Extension to Advance Precision Immune Modulation Platform
核心洞察
Third Arc Bio (搜索) closed a $52 million Series A extension led by Andreessen Horowitz (搜索), bringing total Series A funding to $217 million to expand its oncology and immunology pipeline.
The company's lead asset ARC101, a bispecific T-cell engager targeting CLDN6 (搜索), is currently in Phase 1 dose-escalation studies for advanced solid tumors (搜索).
Third Arc Bio (搜索)'s ARCTag platform uses multispecific antibodies to localize immune modulation directly to disease sites, potentially improving therapeutic index over systemic autoimmune therapies.
Third Arc Bio (搜索) announced the closing of a $52 million Series A extension financing, adding to a previously announced $165 million Series A round as the clinical-stage biotech company expands its oncology and immunology pipeline. The financing was led by new investor Andreessen Horowitz (搜索) (a16z) alongside founding investor Omega Funds (搜索), with participation from Life Sciences at Goldman Sachs Alternatives (搜索), BVF Partners LP, funds managed by abrdn Inc., accounts advised by T. Rowe Price Associates Inc., Marshall Wace, Hillhouse Investment, Galapagos NV, AbbVie Ventures (搜索), and Alderline Group.
As part of the transaction, a16z General Partner Jorge Conde joined Third Arc Bio (搜索)'s board of directors. The company will use proceeds to accelerate its immunology and inflammation portfolio while continuing to advance additional oncology programs into clinical trials.
Precision Immune Modulation Platform
Third Arc Bio (搜索) is developing multifunctional antibodies that generate immune synapses to precisely activate or inhibit T cells, with an emphasis on improved control of immune activity and enhanced efficacy and safety profiles. The company's approach represents what Conde described as "a shift toward more precise immune modulation—moving beyond systemic exposure to therapies designed to deliver highly controlled biological effects at sites of disease."
The company's platform portfolio includes the solid tumor ARCStim Platform and the immunology and inflammation ARCTag Platform. The ARCTag (Tethered Agonist) Platform uses multispecific antibodies to localize immune modulation directly to sites of disease, which Third Arc Bio (搜索) positions as a meaningful advance beyond conventional systemic autoimmune therapies.
Clinical Pipeline Progress
Third Arc Bio (搜索)'s lead asset, ARC101, is a bispecific T-cell engager targeting CLDN6 (搜索) currently in a Phase 1 dose-escalation study in patients with advanced solid tumors (搜索). The company launched in 2022 with seed financing from Omega Funds (搜索) and has since assembled an experienced team spanning drug discovery and development.
"This financing allows us to maintain momentum across our expanding oncology portfolio while rapidly advancing our next-generation I&I assets into first-in-human studies," said Peter F. Lebowitz, MD, PhD, Chief Executive Officer of Third Arc Bio (搜索). "By parallel-tracking programs, we can more efficiently validate the full potential of our platforms, rapidly generate proof-of-concept data, and deliver innovative therapies for patients with significant unmet need."
Strategic Investment Validation
The investment from Andreessen Horowitz (搜索) validates Third Arc Bio (搜索)'s approach to developing biologics that could improve both efficacy and safety across oncology and immune-mediated diseases. Conde emphasized the company's "rigorous, patient-driven approach to building biologics" and highlighted the team's track record of translating complex immunology into approved medicines.
The targeted activity offered by Third Arc Bio (搜索)'s ARCTag platform represents the potential for enhanced efficacy and therapeutic index compared to existing systemic treatments, positioning the company to address significant unmet medical needs in both oncology and autoimmune conditions.